Effect of endogenous estradiol levels on bone resorption and bone resoption

SR MASTAGLIA; A BAGUR; M ROYER; D YANKELEVICH; F SAYEGH; B OLIVERI

CLIMACTERIC

Parthenon Publishing

Año: 2009 vol. 12 p. 49 - 58

1369-7137

ABSTRACT Objective To investigate the effect of endogenous estrogens on bone mineral density (BMD) and bone markers in postmenopausal women over 24 months.To investigate the effect of endogenous estrogens on bone mineral density (BMD) and bone markers in postmenopausal women over 24 months. Methods Fifty out of 99 postmenopausal women seen previously were re-assessed after 24 months. Levels of BMD, bone markers, serum estradiol (E2) and total testosterone were determined.Fifty out of 99 postmenopausal women seen previously were re-assessed after 24 months. Levels of BMD, bone markers, serum estradiol (E2) and total testosterone were determined.2) and total testosterone were determined. Results BMD decreased in the femoral neck (*2%) (p<0.008), but remained stable in the other skeletal areas; E2 and serum Crosslaps (sCTX) decreased by 34% (p<0.001) and 21% (p<0.003), respectively. Women aged65 years exhibited decreased BMD only in the femoral neck (2%, p<0.01), without changes in bone markers. Women aged465 years exhibited a decrease in sCTX levels and stable BMD values at all skeletal sites. E2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.BMD decreased in the femoral neck (*2%) (p<0.008), but remained stable in the other skeletal areas; E2 and serum Crosslaps (sCTX) decreased by 34% (p<0.001) and 21% (p<0.003), respectively. Women aged65 years exhibited decreased BMD only in the femoral neck (2%, p<0.01), without changes in bone markers. Women aged465 years exhibited a decrease in sCTX levels and stable BMD values at all skeletal sites. E2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.2 and serum Crosslaps (sCTX) decreased by 34% (p<0.001) and 21% (p<0.003), respectively. Women aged65 years exhibited decreased BMD only in the femoral neck (2%, p<0.01), without changes in bone markers. Women aged465 years exhibited a decrease in sCTX levels and stable BMD values at all skeletal sites. E2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.p<0.001) and 21% (p<0.003), respectively. Women aged65 years exhibited decreased BMD only in the femoral neck (2%, p<0.01), without changes in bone markers. Women aged465 years exhibited a decrease in sCTX levels and stable BMD values at all skeletal sites. E2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.p<0.01), without changes in bone markers. Women aged465 years exhibited a decrease in sCTX levels and stable BMD values at all skeletal sites. E2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.465 years exhibited a decrease in sCTX levels and stable BMD values at all skeletal sites. E2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.2 levels decreased similarly in both groups (*35%). Women with baseline E2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.2 levels 10 pg/ml showed stable BMD in spite of their E2 levels decreasing by 42% (p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.p<0.001); sCTX decreased by 21% (p<0.01). Women with baseline E2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.2 levels510 pg/ml showed a 2% decrease (p<0.001) in femoral neck BMD and a 19% decrease (p<0.002) in E2 levels, without changes in bone markers.p<0.002) in E2 levels, without changes in bone markers. Conclusion Although endogenous E2 decreased to around 7 pg/ml in these menopausal women, this level would seem to be sufficient to maintain BMD in almost all skeletal areas, and to be more effective in older women.Although endogenous E2 decreased to around 7 pg/ml in these menopausal women, this level would seem to be sufficient to maintain BMD in almost all skeletal areas, and to be more effective in older women.